In the last trading session, 1.0 million Oncternal Therapeutics Inc (NASDAQ:ONCT) shares changed hands as the company’s beta touched 1.36. With the company’s per share price at $2.09 changed hands at $0.66 or 45.64% during last session, the market valuation stood at $6.19M. ONCT’s last price was a discount, traded about -528.71% off its 52-week high of $13.14. The share price had its 52-week low at $1.05, which suggests the last value was 49.76% up since then. When we look at Oncternal Therapeutics Inc’s average trading volume, we note the 10-day average is 0.17 million shares, with the 3-month average coming to 49.90K.
Analysts gave the Oncternal Therapeutics Inc (ONCT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ONCT as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Oncternal Therapeutics Inc’s EPS for the current quarter is expected to be -3.19.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Oncternal Therapeutics Inc (NASDAQ:ONCT) trade information
Instantly ONCT was in green as seen at the end of in last trading. With action 99.05%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -80.51%, with the 5-day performance at 99.05% in the green. However, in the 30-day time frame, Oncternal Therapeutics Inc (NASDAQ:ONCT) is 36.60% up. Looking at the short shares, we see there were 17887.0 shares sold at short interest cover period of 0.19 days.
The consensus price target for the stock as assigned by Wall Street analysts is 28, meaning bulls need an upside of 92.54% from its current market value. According to analyst projections, ONCT’s forecast low is 28 with 28 as the target high. To hit the forecast high, the stock’s price needs a -1239.71% plunge from its current level, while the stock would need to soar -1239.71% for it to hit the projected low.
Oncternal Therapeutics Inc (ONCT) estimates and forecasts
Data shows that the Oncternal Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -76.41% over the past 6 months, a 7.45% in annual growth rate that is considerably lower than the industry average of 17.50%. Year-over-year growth is forecast to reach 108.90% up from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 140k. 2 analysts are of the opinion that Oncternal Therapeutics Inc’s revenue for the current quarter will be 140k. The company’s revenue for the corresponding quarters a year ago was 179k and 297k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -21.80%. The estimates for the next quarter sales put growth at -52.90%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 18.19%. The 2024 estimates are for Oncternal Therapeutics Inc earnings to increase by 11.50%, but the outlook for the next 5-year period is at 0.00% per year.
ONCT Dividends
Oncternal Therapeutics Inc is expected to release its next quarterly earnings report on 2024-Nov-07.
Oncternal Therapeutics Inc (NASDAQ:ONCT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 9.23% of Oncternal Therapeutics Inc shares while 16.33% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 17.99%.
Among Mutual Funds, the top two as of Jun 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . With 107.99 shares estimated at $0.23 million under it, the former controlled 3.65% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 1.05% of the shares, roughly 31.06 shares worth around $64917.0.
